Results 71 to 80 of about 10,082 (205)

One Week Exposure to a Somatostatin Receptor 2 Antagonist (SSTR2a) Enhances Glucagon Counterregulation to Insulin‐Induced Hypoglycaemia and Does Not Worsen Glycemia in a Male Rat Model of Insulin‐Requiring Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8208-8218, September 2026.
ABSTRACT Introduction Administration of a somatostatin receptor 2 antagonist (SSTR2a) increases glucagon responsiveness to hypoglycaemia in insulin‐treated type 2 diabetes (T2D), but the durability of this effect and the impact of repeated SSTR2a dosing on overall glycaemia in T2D are unclear.
Ninoschka C. D'Souza   +7 more
wiley   +1 more source

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Central Saudi Arabia cohort of the A 1 chieve study

open access: yesIndian Journal of Endocrinology and Metabolism, 2013
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Muhamed Shahed Omar   +2 more
doaj   +1 more source

Impact of system updates for sensor‐augmented pump therapy on glycemic management in Japanese individuals with type 1 diabetes (SAP‐J T1D study)

open access: yesJournal of Diabetes Investigation, Volume 17, Issue 9, Page 1499-1505, September 2026.
Sequential updates from MiniMed 620G to 640G and then to 770G were associated with stepwise improvements in glycemic management in Japanese individuals with type 1 diabetes. The transition to MiniMed 640G was mainly associated with reduced hypoglycemia, whereas the subsequent transition to MiniMed 770G was associated with reduced hyperglycemia.
Shuichiro Saito   +9 more
wiley   +1 more source

Faster aspart insulin (fiasp®)

open access: yes, 2018
peer reviewedFast-acting insulin aspart (faster aspart), commercialized under the trade name of Fiasp(R), is insulin aspart in a new formulation aiming to mimic the physiologic prandial insulin release more closely than currently available rapid-acting ...
Scheen, André, Paquot, Nicolas
core  

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Oman cohort of the A 1 chieve study

open access: yesIndian Journal of Endocrinology and Metabolism, 2013
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Mustafa Al Abousi
doaj   +1 more source

Medication Burden: Beyond Counts to Recognize Polypharmacy as an Inherent Part of Living With Chronic Kidney Disease

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 139, Issue 2, August 2026.
ABSTRACT Medication burden in older patients with chronic kidney disease (CKD) is substantial, and simple medication counts are insufficient for identifying those at elevated risk of inappropriate prescribing. This study characterized medication burden by assessing the number of medications, potentially inappropriate medications (PIMs) and ...
Morten Baltzer Houlind   +4 more
wiley   +1 more source

Use of short-acting insulin aspart in managing older people with diabetes

open access: yes, 2009
Eltayeb Marouf, Alan J SinclairInstitute of Diabetes for Older People – IDOP, Bedfordshire and Hertfordshire Postgraduate Medical School, University of Bedfordshire, UKAbstract: Type 2 diabetes mellitus affects 5.9% of the world adult population ...
Eltayeb Marouf, Alan J Sinclair
core  

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Andhra Pradesh cohort of the A 1 chieve study

open access: yesIndian Journal of Endocrinology and Metabolism, 2013
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Mohammed Abubaker   +4 more
doaj   +1 more source

Photoinactivation of Aspartate Aminotransferase

open access: yesJournal of Biological Chemistry, 1970
Abstract The cofactor pyridoxal 5'-phosphate bound through an aldimine linkage to lysine residues of the enzyme aspartate aminotransferase is very stable to irradiation with light of 420 nm. The catalytic function of the enzyme exposed to light absorbed by the cofactor remains unaffected, indicating that pyridoxal 5'-phosphate is not an efficient ...
N, Burridge, J E, Churchich
openaire   +2 more sources

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Abu Dhabi cohort of the A 1 chieve study

open access: yesIndian Journal of Endocrinology and Metabolism, 2013
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Oula Alhabian, Mowafaq Yehyia
doaj   +1 more source

Home - About - Disclaimer - Privacy